Health Economics›Marginal zone lymphoma›Relapsed or refractory non-randomized or retrospective data

Relapsed or refractory non-randomized or retrospective data

Marginal zone lymphoma · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Ibrutinib monotherapy Variant #01	—	R 80 133	28d	~44.1 mo	—	~48	~R 3 846 377 PFS proxy · indirect	15
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	—	—	4
Bendamustine and Rituximab (BR) Variant #12	—	R 40 807	28d	~39.6 mo	—	~44	~R 1 795 506 PFS proxy · indirect	18
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
Ox-P Variant #01	—	R 1 418	21d	—	—	—	—	—
Copanlisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—
Vorinostat monotherapy Variant #01 Partial	—	—	28d	~3.1 mo	—	~4	—	1
Idelalisib monotherapy Variant #01 Partial	—	—	28d	—	—	—	—	—

8 of 8 regimens shown